Prognostic factors in soft tissue sarcoma

Seminars in Surgical Oncology

Volumn 17, Issue 1, 1999, Pages 23-32

  Levine, Edward A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Biological tumor markers; Cell cycle; Disease free survival; DNA; Ki 67 antigen; Lymph node metastasis; MDR genes; Myc genes; Neoplasm proteins; Neoplasm staging; P glycoprotein; P53 genes; Ploidies; Prognosis; Proto oncogenes; Ras genes; Retinoblastoma genes; S phase; Sarcoma; Soft tissue neoplasms; Tumor suppressor genes

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

CANCER STAGING; METASTASIS; ONCOGENE C ERB; ONCOGENE MYC; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; TUMOR LOCALIZATION; TUMOR VOLUME;

CELL CYCLE; GENETIC MARKERS; HUMANS; PLOIDIES; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE;

EID: 0033014663     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199907/08)17:1<23::AID-SSU4>3.0.CO;2-R     Document Type: Review

References (76)

1. Russell WO, Cohen J, Enzinger F, et al: A clinical and pathological staging system for soft tissue sarcoma. Cancer 1977;40:1562-1570.
2. Enneking WP, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; (153):106-120.
3. th ed. Philadelphia: Lippincott-Raven; 1997.
4. nd ed. Stamford, Connecticut: Appleton & Lange; 1998. p. 201-225.
5. th ed. Philadelphia: Lippincott; 1992.
6. Coindre JM, Terrier P, Bui NB, et al: Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996;14:869-877.
7. Tran LM, Mark R, Meier R, et al: Sarcomas of the head and neck. Prognostic factors and treatment strategies. Cancer 1992;70:169-177.
8. Tomita Y, Kuratsu S, Naka N, et al: A staging system for soft-tissue sarcoma and its evaluation in relation to treatment. Int J Cancer 1994;58:168-173.
9. Enzinger FM. Weiss SW (eds): "Tumors of the soft tissues." 3rd ed. St. Louis, MO: Mosby-Year Book; 1995. p. 6-16.
10. Broders AC, Hargrave R, Meyerding HW: Pathological features of soft tissue fibrosarcoma with special reference to the grading of its malignancy. Surg Gynecol Obstet 1939;69:267-280.
11. Mandard AM, Chasle J, Mandard JC, et al: The pathologist's role in a multidisciplinary approach for soft tissue sarcoma: a reappraisal (39 cases). J Surg Oncol 1981;17:69-81.
12. Markhede G, Angervall L, Stener B: A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 1982;49:1721-1733.
13. Trojani M, Contesso G, Coindre JM, et al: Soft-tissue sarcomas of adults: Study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37-42.
14. Costa J, Wesley RA, Glatstein E, Rosenberg SA: The grading of soft tissue sarcomas. Cancer 1984;53:530-541.
15. Guillou L, Coindre JM, Bonichon F, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1996;15:350-362.
16. Shiu MH, Castro EB, Hajdu SI, Fortner JG: Surgical treatment of 297 soft tissue sarcomas of the lower extremity. Ann Surg 1975; 182:597-602.
17. Rooser B, Attewell R, Berg NO, Rydholm A: Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 1988;61:817-823.
18. Torosian MH, Friedrich C, Godbold J, et al: Soft-tissue Sarcoma: initial characteristics and prognostic factors in patients with and without metastatic disease. Semin Surg Oncol 1988;4:13-19.
19. Pisters PW, Leung DH, Woodruff J, et al: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-1689.
20. Heslin MJ, Cordon-Cardo C, Lewis JJ, et al: Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 1998;83:490-497.
21. Mazeron JJ, Suit HD: Lymph nodes as sites of metastases from sarcomas of soft tissue [Review]. Cancer 1987;60:1800-1808.
22. Roth JA, Putnam JB Jr, Wesley MN, Rosenberg SA: Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer 1985;55:1361-1366.
23. Putnam JB Jr, Roth JA: Resection of sarcomatous pulmonary metastases. Surg Oncol Clinics North Am 1993;2:673-691.
24. Rosenberg SA, Seipp CA, White DE, Wesley R: Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcoma of the extremities. J Clin Oncol 1985;3:698-709.
25. Heslin MJ, Gaynor JJ Newman E, et al: Effect of perioperative blood transfusion on recurrence and survival in 232 primary high-grade extremity sarcoma patients. Ann Surg Oncol 1994;1:189-194.
26. Rooser B, Gustafson P, Rydholm A: Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma? Cancer 1990;65:1727-1729.
27. Gaynor JJ, Tan CC, Casper ES, et al: Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317-1329.
28. Van Glabbeke M, Oosterom AT, Olsterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999;17:150-157.
29. Levine EA, Holzmayer T, Bacus S, et al: Evaluation of newer prognostic markers for adult soft tissue sarcoma. J Clin Oncol 1997;15:3249-3257.
30. Kreicbergs A, Tribukait B, Willems J, Bauer HC: DNA flow analysis of soft tissue tumors. Cancer 1987;59:128-133.
31. Matsuno T, Gebhardt MC, Schiller AL, et al: The use of flow cytometry as a diagnostic aid in the management of soft-tissue tumors. J Bone Joint Surg [Am] 1988;70:751-759.
32. Ueda T, Aozasa K, Tsujimoto M, et al: Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989;63:1607-1611.
33. Alvegard TA, Berg NO, Baldetorp B, et al: Cellular DNA content and prognosis of high-grade soft tissue sarcoma: The Scandinavian Sarcoma Group experience. J Clin Oncol 1990;8:538-547.
34. Bauer HC, Kreicbergs A, Tribukait B: DNA content prognostic in soft tissue sarcoma, 102 patients followed for 1-10 years. Acta Orthop Scand 1991;62:187-194.
35. Pappo AS, Crist WM, Kuttesch J, et al: Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group [published erratum appears in J Clin Oncol 1994;12:440]. J Clin Oncol 1993;11:1901-1905.
36. Kuratsu S, Tomita Y, Myoui A, et al: DNA ploidy pattern and cell cycle stage of tumor cells in soft-tissue sarcomas: Clinical implications. Oncology 1995;52:363-370.
37. Levine EA, Roninson IB, Kim DK, et al: MDR-1 expression in soft tissue sarcoma. Surg Forum 1994;45:503-505.
38. Kilpatrick SE, Teot LA, Geisinger KR, et al: Relationship of DNA ploidy to histology and prognosis in rhabdomyosarcoma. Comparison of flow cytometry and image analysis. Cancer 1994;74:3227-3233.
39. el-Naggar AK, Garcia GM: Epithelioid sarcoma. Flow cytometric study of DNA content and regional DNA heterogeneity. Cancer 1992;69:1721-1728.
40. Barrios C, Castresana JS, Falkmer UG, et al: c-myc oncogene amplification and cytometric DNA ploidy pattern as prognostic factors in musculoskeletal neoplasms. Int J Cancer 1994;58:781-786.
41. Schmidt RA, Conrad EU 3rd, Collins C, et al: Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 1993;72:2593-2601.
42. Kroese MC, Rutgers DH, Wils IS, et al: The relevance of the DNA index and proliferation rate in the grading of benign and malignant soft tissue tumors. Cancer 1990;65:1782-1788.
43. Drobnjak M, Latres E, Pollack D, et al: Prognostic implications of p53 overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549-554.
44. Zehr RJ, Bauer TW, Marks KE, Weltevreden A: Ki-67 and grading of malignant fibrous histiocytomas. Cancer 1990;66:1984-1990.
45. Hall A: The cellular functions of small GTP-binding proteins [Review]. Science 1990;249(4969):635-640.
46. Pulciani S, Santos E, Lauver AV, et al: Oncogenes in solid human tumors. Nature 1982;300(5892):539-542.
47. Hill MA, Gong C, Casey TJ, et al: Detection of K-ras mutations in rejected primary leiomyosarcoma. Cancer Epidemiol Prev 1997;6:1095-1100.
48. Coussens L, Yang-Fen TL, Liao YC, et al: Tyrosinase receptor with extensive homology to the EGF receptor shares chromosomal location with the neu oncogene. Science 1985;230(4730):1132-1139.
49. uda RB, Cundiff D, August CZ, et al: Growth factor receptor and related oncogene determination in mesenchymal tumors. Cancer 1993;71:3526-3530.
50. Persson H, Leder P: Nuclear localization and DNA binding properties of a protein expressed by human c-myc oncogene. Science 1984;225(4663):718-721.
51. Ozaki T, Ikeda S, Kuwai A, et al: Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue sarcomas. Cell Mol Biol 1993:39:235-242.
52. Dias P, Kumar P, Marsden HB, et al: N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer 1990;45:593-596.
53. Garson JA, Clayton J, McIntyre P, Kempshead JT: N-myc oncogene amplification in rhabdomyosarcoma at release [letter]. Lancet 1986;1(8496):1496.
54. Barrios C, Castresana JS, Kriecbergs A: Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification. Am J Clin Oncol 1994;17:273-276.
55. Oliner JD. Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358(6381):80-83.
56. Condon-Cardo C, Latres E, Drobnjak M, et al: Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799.
57. Nakayama T, Toguchida J, Wadayama B, et al: MDM2 gene amplification in bone and soft tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 1995;64:342-346.
58. Hieken TJ, Das Gupta TK: Co-expression of mutant p53 and MDM2 proteins in liposarcoma. Surg Forum 1996;47:500-501.
59. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342(6250):705-708.
60. Bartek J, Bartkova J, Vojtesek B. et al: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-1703.
61. Leach FS, Tokino T, Meltzer P, et al: p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53(10 Suppl):2231-2234.
62. Wadayama B, Toguchida J, Yamaguchi T, et al: p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993;68:1134-1139.
63. Hieken TJ, Das Gupta TK: Mutant p53 expression: A marker of diminished survival in well-differentiated soft tissue sarcoma. Clin Cancer Res 1996;2:1391-1395.
64. Karpeh MS, Brennan MF, Cance WG, et al: Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986-991.
65. De Chiara A, T'Ang A, Triche TJ: Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas. J Natl Cancer Inst 1993;85:152-157.
66. Pastan I, Gottesman M: Multiple-drug resistance in human cancer [Review]. N Engl J Med 1987;316:1388-1393.
67. Roninson IB (ed): "Molecular and cellular biology of multidrug resistance in tumor cells." New York, NY: Plenum Press; 1991. p. 189-198.
68. Chan HS, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycoprotein: prognostic correlation of soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
69. Gerlach JH, Bell DR, Karakousis C, et al: P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987; 5:1452-1460.
70. Cordon-Cardo C, O'Brien JP, Boccia J, et al: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor-tissues. J Histochem Cytochem 1990;38:1277-1287.
71. Roessner A, Ueda Y, Bockhorn-Dworniczak B, et al: Prognostic implication of immunodetection of P-glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol 1993;119:185-189.
72. Baldini N, Scotlandi K, Barbanti-Brodano G, et al: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-1385.
73. Pinedo HM, Giaccone G: P-glycoprotein - A marker of cancer-cell behavior [editorial]. N Engl J Med 1995;333:1417-1419.
74. Brueninger LM, Paul S, Gaughan K, et al: Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 1995;55:5342-5347.
75. Nooter K, Westerman AM, Flens MJ, et al: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995;1:1301-1310.
76. Armstrong DK, Gordon GB, Hilton J, et al: Hepsulfam sensitivity in human breast cancer cell lines: The role of glutathione and glutathione S-transferase in resistance. Cancer Res 1992;52:1416-1421.